RxDoctor Payments Data

John Kelly, MD

Family Medicine · Forest, VANPI 1972952125

Payments from drug & device makers

$10,163in general payments, 2019–2025

Across 610 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Pfizer$875
  • AbbVie$738
  • Johnson & Johnson$718
  • Lilly USA, LLC$602
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$10,163100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,163 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$240,933
Medicare patients
542
Services billed
5,879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$99,828
EliquisApixaban86$95,571
FarxigaDapagliflozin Propanediol54$47,562
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$34,078
JardianceEmpagliflozin24$26,086
TrulicityDulaglutide21$20,630
XareltoRivaroxaban11$16,867
MounjaroTirzepatide13$13,214
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$9,966
Atorvastatin Calcium729$5,920
Praluent PenAlirocumab11$5,746
Potassium Chloride45$5,112
PaxlovidNirmatrelvir/Ritonavir12$4,206
Lidocaine18$3,171
Rosuvastatin Calcium258$2,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,250$99,82874 claims
PfizerEliquis, Paxlovid$875$99,77798 claims
AstraZenecaFarxiga$1,024$47,56254 claims
GSKTrelegy Ellipta$565$34,07835 claims
Lilly USA, LLCTrulicity, Mounjaro$602$33,84334 claims
Boehringer IngelheimJardiance$515$26,08624 claims
Johnson & JohnsonXarelto$718$16,86711 claims
AbbVieSynthroid$738$2,24038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Forest

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →